Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS - it works but is it different from existing IL-1
Tweet Content
Bimekizumab is a dual IL-17A and IL-17F inhibitor, for nr-axSpA and AS
- it works but is it different from existing IL-17i?
- appears to work well in TNFi-inadequate responders
- are TNFi-IR pts immunologically different?
#RNL2023 https://t.co/bHboX3Xz6M https://t.co/kCa9MbFdxs
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off